● “Shareholders want [GSK] to become a bigger, better pharmaceuticals business,” says Chris Hughes on Bloomberg. “Yet it has neither grown nor shrunk to greatness.” Ten years ago, it was worth twice as much as AstraZeneca; now it’s worth
City talk
Jul 28, 2023
1 minute
You’re reading a preview, subscribe to read more.
Start your free 30 days